Cardiac Surgery, Infective Endocarditis, Outcomes
Conditions
Keywords
Infective Endocarditis, Registry, European, Surgery, Prognosis
Brief summary
This is a prospective, multicentric, european registry of patients with infective endocarditis undergoing cardiac surgery. Patient demographics, clinical data and laboratory values will be collected, as well as treatment outcomes at day 30, day 90 and 1-5 years after the intervention.
Detailed description
Infective endocarditis (IE) is now a relatively rare but worldwide disease (3-10 IE/100000 population/year) with increasing incidence especially in the Western world. IE is still associated with high morbidity and mortality, prolonged hospital stay, high risk of reinfection, significantly worsened prognosis for patients, substantially reduced quality of life, and in any case represents a major financial burden for the respective healthcare systems \[1-11\]. Patients who need to undergo cardiac surgery due to infective endocarditis (IE) are heterogeneous and present with a persistently high perioperative morbidity and mortality rate. Despite optimal and individualized perioperative management strategies, perioperative complications such as heart failure, systemic inflammatory response, vasoplegia, and sepsis is still the main reason for adverse outcomes following cardiac surgery. The present European, multicenter IE registry (Surgical RegistRy of infective ENDocarditis in EuRope - SURRENDER) was initiated and established to record and appropriately analyze current surgical treatment options and perioperative adjunctive treatment strategies, as well as short- and long-term patient outcomes.
Interventions
PROCEDURECardiac surgery
Patients with infective endocarditis undergoing open heart surgery
Sponsors
University Hospital, Essen
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Patients with infective endocarditis (according to DUKE criteria) undergoing cardiac surgery * Age ≥18 years * Written informed consent
Exclusion criteria
* Age \< 18 years * Missing declaration of consent * Current participation in another interventional trial
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| In-hospital mortality (all cause) | 30 days or during index hospitalization | Overall mortality rate in-hospital, at day 30 or during index hospitalization |
| Mortality at long-term follow-up | 1 to 5 years | at 1 to 5 years post-surgery |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Sepsis accociated mortatilty | 30 days or during index hospitalization | Sepsis accociated mortatilty at day 30 or during index hospitalization |
| Post-operative sepsis | 30 days or during index hospitalization | Sepsis at day 30 or during index hospitalization |
| Vasoactive inotropic score | < 72h post-surgery | The sum of maximum dose rates of inotropes and/or vasopressor medications administered the first 72h post-surgery |
| MACCE | 30 days or during index hospitalization | Major adverse cardiac and cerebrovascular event rate at day 30 or during index hospitalization. Composite of 1.) Cardiac events: (postoperative myocardial infarction, CPR, LCOS/heart failure, repeat cardiac surgery) and/or cerebrovascular events (postoperative stroke, TIA, intracranial hemorrhage) |
| Readmission due to IE recurrence | 30 days to 1 year post-surgery | Recurrence of infective endocarditis after 30 days to 1 year post-surgery |
| Renal failure | 30 days or during index hospitalization | Occurence of renal failure (KDIGO criteria) |
| Dialysis (RRT post-surgery) | 30 days or during index hospitalization | Occurence of renal failure requiring renal replacement therapy |
| Mechanical ventilation time | 30 days or during index hospitalization | Duration of postoperative invasive/mechanical ventilation post-surgery |
| MACCE at long term follow-up | 1 to 5 years | Major adverse cardiac and cerebrovascular event rate at 1 to 5 years post-surgery |
Countries
Germany
Contacts
Primary ContactMatthias Thielmann, Prof. Dr.
Backup ContactWolfgang Ristau
Outcome results
None listed